A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Clinical trial NCT06926920 · RECRUITING
Trial details
- NCT number
- NCT06926920
- Sponsor
- Gilead Sciences
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-30
- Primary completion
- 2028-06-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.